Purpose: We initiated a clinical trial to determine the proportion of breast cancer survivors achieving ≥5% weight loss using a remotely delivered weight loss intervention (POWER-remote) or a self-directed approach, and to determine the effects of the intervention on biomarkers of cancer risk including metabolism, inﬂammation, and telomere length. Experimental Design: Women with stage 0-III breast cancer, who completed local therapy and chemotherapy, with a body mass index ≥25 kg/m2 were randomized to a 12-month intervention (POWER-remote) versus a self-directed approach. The primary objective was to determine the number of women who achieved at least 5% weight loss at 6 months. We assessed baseline and 6-month change in a panel of adipocytokines (adiponectin, leptin, resistin, HGF, NGF, PAI1, TNFa, MCP1, IL1b, IL6, and IL8), metabolic factors (insulin, glucose, lipids, hsCRP), and telomere length in peripheral blood mononuclear cells. Results: From 2013 to 2015, 96 women were enrolled, and 87 were evaluable for the primary analysis; 45 to POWER-remote and 42 to self-directed. At 6 months, 51% of women randomized to POWER-remote lost ≥5% of their baseline body weight, compared with 12% in the self-directed arm [OR, 7.9; 95% conﬁdence interval (CI), 2.6-23.9; P ¼ 0.0003]; proportion were similar at 12 months (51% vs 17%, respectively, P ¼ 0.003). Weight loss correlated with signiﬁcant decreases in leptin, and favorable modulation of inﬂammatory cytokines and lipid proﬁles. There was no signiﬁcant change in telomere length at 6 months. Conclusions: A remotely delivered weight loss intervention resulted in signiﬁcant weight loss in breast cancer survivors, and favorable effects on several biomarkers.
ASJC Scopus subject areas
- Cancer Research